{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T18:28:06Z","timestamp":1794940086774,"version":"4.9.1"},"reference-count":254,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1038\/s41573-023-00692-8","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T06:02:57Z","timestamp":1683871377000},"page":"585-603","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":227,"title":["Accelerating antiviral drug discovery: lessons from COVID-19"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7699-8140","authenticated-orcid":false,"given":"Annette","family":"von Delft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5073-442X","authenticated-orcid":false,"given":"Matthew D.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann D.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9565-2030","authenticated-orcid":false,"given":"Lisa A.","family":"Purcell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar Singh","family":"Saikatendu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uli","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Tallarico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpha A.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"692_CR1","doi-asserted-by":"crossref","first-page":"m3389","DOI":"10.1136\/bmj.m3389","volume":"371","author":"R Gibb","year":"2020","unstructured":"Gibb, R., Franklinos, L. H. V., Redding, D. W. & Jones, K. E. Ecosystem perspectives are needed to manage zoonotic risks in a changing climate. Br. Med. J. 371, m3389 (2020).","journal-title":"Br. Med. J."},{"key":"692_CR2","unstructured":"Vidal, J. Destroyed habitat creates the perfect conditions for coronavirus to emerge. [Reprinted from Ensia] Scientific American https:\/\/www.scientificamerican.com\/article\/destroyed-habitat-creates-the-perfect-conditions-for-coronavirus-to-emerge\/ (18 March 2020)."},{"key":"692_CR3","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s41564-019-0476-8","volume":"4","author":"JP Messina","year":"2019","unstructured":"Messina, J. P. et al. The current and future global distribution and population at risk of dengue. Nat. Microbiol. 4, 1508\u20131515 (2019).","journal-title":"Nat. Microbiol."},{"key":"692_CR4","doi-asserted-by":"crossref","unstructured":"Goldin, I. & Mariathasan, M. The Butterfly Defect: How Globalization Creates Systemic Risks, and What to Do about It (Princeton Univ. Press, 2015).","DOI":"10.1515\/9781400850204"},{"key":"692_CR5","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.antiviral.2018.05.005","volume":"155","author":"S Chaudhuri","year":"2018","unstructured":"Chaudhuri, S., Symons, J. A. & Deval, J. Innovation and trends in the development and approval of antiviral medicines: 1987\u20132017 and beyond. Antiviral Res. 155, 76\u201388 (2018).","journal-title":"Antiviral Res."},{"key":"692_CR6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","volume":"583","author":"DE Gordon","year":"2020","unstructured":"Gordon, D. E. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583, 459\u2013468 (2020).","journal-title":"Nature"},{"key":"692_CR7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280.e8 (2020).","journal-title":"Cell"},{"key":"692_CR8","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1001\/jama.2020.8920","volume":"323","author":"FS Collins","year":"2020","unstructured":"Collins, F. S. & Stoffels, P. Accelerating COVID-19 therapeutic interventions and vaccines (ACTIV): an unprecedented partnership for unprecedented times. JAMA 323, 2455\u20132457 (2020). An example of adaptive clinical trial designs greatly used early in the SARS-CoV-2 pandemic.","journal-title":"JAMA"},{"key":"692_CR9","doi-asserted-by":"crossref","first-page":"e00168-19","DOI":"10.1128\/CMR.00168-19","volume":"33","author":"N Kumar","year":"2020","unstructured":"Kumar, N. et al. Host-directed antiviral therapy. Clin. Microbiol. Rev. 33, e00168-19 (2020).","journal-title":"Clin. Microbiol. Rev."},{"key":"692_CR10","doi-asserted-by":"crossref","unstructured":"Wood, A. & Armour, D. In Progress in Medicinal Chemistry (eds King, F. D. & Lawton, G.) 239\u2013271 (Elsevier, 2005).","DOI":"10.1016\/S0079-6468(05)43007-6"},{"key":"692_CR11","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/hep.21102","volume":"43","author":"J Paeshuyse","year":"2006","unstructured":"Paeshuyse, J. et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 43, 761\u2013770 (2006).","journal-title":"Hepatology"},{"key":"692_CR12","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/infdis\/jiab305","volume":"224","author":"MD Hall","year":"2021","unstructured":"Hall, M. D. et al. Report of the National Institutes of Health SARS-CoV-2 antiviral therapeutics summit. J. Infect. Dis. 224, S1\u2013S21 (2021).","journal-title":"J. Infect. Dis."},{"key":"692_CR13","unstructured":"NIAID pandemic preparedness plan targets \u201cprototype\u201d and priority pathogens. NIAID https:\/\/www.niaid.nih.gov\/news-events\/niaid-pandemic-preparedness-plan-targets-prototype-and-priority-pathogens (2022)."},{"key":"692_CR14","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41586-020-2665-2","volume":"588","author":"Z Ke","year":"2020","unstructured":"Ke, Z. et al. Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature 588, 498\u2013502 (2020).","journal-title":"Nature"},{"key":"692_CR15","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"692_CR16","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.81702","volume":"11","author":"KA Dolan","year":"2022","unstructured":"Dolan, K. A. et al. Structure of SARS-CoV-2 M protein in lipid nanodiscs. eLife 11, e81702 (2022).","journal-title":"eLife"},{"key":"692_CR17","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/22221751.2020.1870414","volume":"10","author":"M Moustaqil","year":"2021","unstructured":"Moustaqil, M. et al. SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species. Emerg. Microbes Infect. 10, 178\u2013195 (2021).","journal-title":"Emerg. Microbes Infect."},{"key":"692_CR18","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","volume":"65","author":"Y Unoh","year":"2022","unstructured":"Unoh, Y. et al. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J. Med. Chem. 65, 6499\u20136512 (2022). Describes the discovery of an oral non-covalent SARS-CoV-2 specific main protease inhibitor now in phase III trials.","journal-title":"J. Med. Chem."},{"key":"692_CR19","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.29.339317","author":"The COVID Moonshot Consortium","year":"2023","unstructured":"The COVID Moonshot Consortium. Open science discovery of oral non-covalent SARS-CoV-2 main protease inhibitor therapeutics. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.10.29.339317 (2023).","journal-title":"bioRxiv"},{"key":"692_CR20","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1128\/AAC.47.12.3907-3916.2003","volume":"47","author":"FG Hayden","year":"2003","unstructured":"Hayden, F. G. et al. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob. Agents Chemother. 47, 3907\u20133916 (2003).","journal-title":"Antimicrob. Agents Chemother."},{"key":"692_CR21","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1039\/D1MD00066G","volume":"12","author":"H Yang","year":"2021","unstructured":"Yang, H. & Yang, J. A review of the latest research on Mpro targeting SARS-COV inhibitors. RSC Med. Chem. 12, 1026\u20131036 (2021).","journal-title":"RSC Med. Chem."},{"key":"692_CR22","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","volume":"59","author":"T Pillaiyar","year":"2016","unstructured":"Pillaiyar, T., Manickam, M., Namasivayam, V., Hayashi, Y. & Jung, S.-H. An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy. J. Med. Chem. 59, 6595\u20136628 (2016).","journal-title":"J. Med. Chem."},{"key":"692_CR23","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1038\/s41467-021-26239-2","volume":"12","author":"B Boras","year":"2021","unstructured":"Boras, B. et al. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nat. Commun. 12, 6055 (2021).","journal-title":"Nat. Commun."},{"key":"692_CR24","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","volume":"63","author":"RL Hoffman","year":"2020","unstructured":"Hoffman, R. L. et al. Discovery of ketone-based covalent inhibitors of Coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19. J. Med. Chem. 63, 12725\u201312747 (2020).","journal-title":"J. Med. Chem."},{"key":"692_CR25","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen, D. R. et al. An oral SARS-CoV-2 M inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586\u20131593 (2021). Describes the discovery of the first oral covalent SARS-CoV-2 specific main protease inhibitor under EUA.","journal-title":"Science"},{"key":"692_CR26","volume":"12","author":"Y Kim","year":"2016","unstructured":"Kim, Y. et al. Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum Coronavirus protease inhibitor. PLoS Pathog. 12, e1005531 (2016).","journal-title":"PLoS Pathog."},{"key":"692_CR27","doi-asserted-by":"crossref","first-page":"11754","DOI":"10.1128\/JVI.01348-12","volume":"86","author":"Y Kim","year":"2012","unstructured":"Kim, Y. et al. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J. Virol. 86, 11754\u201311762 (2012).","journal-title":"J. Virol."},{"key":"692_CR28","doi-asserted-by":"crossref","first-page":"113201","DOI":"10.1016\/j.ejmech.2021.113201","volume":"213","author":"L Tian","year":"2021","unstructured":"Tian, L. et al. RNA-dependent RNA polymerase (RdRp) inhibitors: the current landscape and repurposing for the COVID-19 pandemic. Eur. J. Med. Chem. 213, 113201 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"692_CR29","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel, J. H. et al. Remdesivir for the treatment of Covid-19 - final report. N. Engl. J. Med. 383, 1813\u20131826 (2020).","journal-title":"N. Engl. J. Med."},{"key":"692_CR30","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","volume":"386","author":"A Jayk Bernal","year":"2022","unstructured":"Jayk Bernal, A. et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N. Engl. J. Med. 386, 509\u2013520 (2022).","journal-title":"N. Engl. J. Med."},{"key":"692_CR31","doi-asserted-by":"crossref","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","volume":"9","author":"TP Sheahan","year":"2017","unstructured":"Sheahan, T. P. et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. 9, eaal3653 (2017). Demonstrates the broad-spectrum antiviral efficacy of remdesivir against both epidemic and zoonotic coronaviruses.","journal-title":"Sci. Transl. Med."},{"key":"692_CR32","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13940-6","volume":"11","author":"TP Sheahan","year":"2020","unstructured":"Sheahan, T. P. et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. 11, 222 (2020).","journal-title":"Nat. Commun."},{"key":"692_CR33","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3390\/v11040326","volume":"11","author":"EP Tchesnokov","year":"2019","unstructured":"Tchesnokov, E. P., Feng, J. Y., Porter, D. P. & G\u00f6tte, M. Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses 11, 326 (2019).","journal-title":"Viruses"},{"key":"692_CR34","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","volume":"368","author":"W Yin","year":"2020","unstructured":"Yin, W. et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science 368, 1499\u20131504 (2020).","journal-title":"Science"},{"key":"692_CR35","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","volume":"28","author":"F Kabinger","year":"2021","unstructured":"Kabinger, F. et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat. Struct. Mol. Biol. 28, 740\u2013746 (2021). Discusses the differential antiviral mechanism of action on the RdRp in causing downstream mutagenesis.","journal-title":"Nat. Struct. Mol. Biol."},{"key":"692_CR36","volume":"22","author":"CTR Vegivinti","year":"2022","unstructured":"Vegivinti, C. T. R. et al. Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials. BMC Infect. Dis. 22, 107 (2022).","journal-title":"BMC Infect. Dis."},{"key":"692_CR37","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.04.135046","author":"KR Brimacombe","year":"2020","unstructured":"Brimacombe, K. R. et al. An OpenData portal to share COVID-19 drug repurposing data in real time. Preprint at\u00a0bioRxiv\u00a0https:\/\/doi.org\/10.1101\/2020.06.04.135046 (2020).","journal-title":"bioRxiv"},{"key":"692_CR38","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1021\/acs.jproteome.1c00206","volume":"20","author":"S Yazdani","year":"2021","unstructured":"Yazdani, S. et al. Genetic variability of the SARS-CoV-2 pocketome. J. Proteome Res. 20, 4212\u20134215 (2021).","journal-title":"J. Proteome Res."},{"key":"692_CR39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003030","volume":"8","author":"JJ Arnold","year":"2012","unstructured":"Arnold, J. J. et al. Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides. PLoS Pathog. 8, e1003030 (2012).","journal-title":"PLoS Pathog."},{"key":"692_CR40","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","volume":"587","author":"D Shin","year":"2020","unstructured":"Shin, D. et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 587, 657\u2013662 (2020).","journal-title":"Nature"},{"key":"692_CR41","doi-asserted-by":"crossref","first-page":"16119","DOI":"10.1073\/pnas.0805240105","volume":"105","author":"K Ratia","year":"2008","unstructured":"Ratia, K. et al. A noncovalent class of papain-like protease\/deubiquitinase inhibitors blocks SARS virus replication. Proc. Natl Acad. Sci. USA 105, 16119\u201316124 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"692_CR42","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-21060-3","volume":"12","author":"J Osipiuk","year":"2021","unstructured":"Osipiuk, J. et al. Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. Nat. Commun. 12, 743 (2021).","journal-title":"Nat. Commun."},{"key":"692_CR43","first-page":"855","volume":"28","author":"H Shan","year":"2021","unstructured":"Shan, H. et al. Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2. Cell. Chem. Biol. 28, 855\u2013865.e9 (2021).","journal-title":"Chem. Biol."},{"key":"692_CR44","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1021\/acs.jmedchem.1c01307","volume":"65","author":"Z Shen","year":"2022","unstructured":"Shen, Z. et al. Design of SARS-CoV-2 PLpro inhibitors for COVID-19 antiviral therapy leveraging binding cooperativity. J. Med. Chem. 65, 2940\u20132955 (2022).","journal-title":"J. Med. Chem."},{"key":"692_CR45","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1021\/acscentsci.1c00519","volume":"7","author":"C Ma","year":"2021","unstructured":"Ma, C. et al. Discovery of SARS-CoV-2 Papain-like protease Inhibitors through a combination of high-throughput screening and a FlipGFP-based reporter assay. ACS Cent. Sci. 7, 1245\u20131260 (2021).","journal-title":"ACS Cent. Sci."},{"key":"692_CR46","doi-asserted-by":"crossref","first-page":"39578","DOI":"10.1074\/jbc.C300328200","volume":"278","author":"JA Tanner","year":"2003","unstructured":"Tanner, J. A. et al. The severe acute respiratory syndrome (SARS) coronavirus NTPase\/helicase belongs to a distinct class of 5\u2019 to 3\u2019 viral helicases. J. Biol. Chem. 278, 39578\u201339582 (2003).","journal-title":"J. Biol. Chem."},{"key":"692_CR47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41580-021-00432-z","volume":"23","author":"B Malone","year":"2022","unstructured":"Malone, B., Urakova, N., Snijder, E. J. & Campbell, E. A. Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design. Nat. Rev. Mol. Cell. Biol. 23, 21\u201339 (2022).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"692_CR48","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.cell.2020.07.033","volume":"182","author":"J Chen","year":"2020","unstructured":"Chen, J. et al. Structural basis for helicase-polymerase coupling in the SARS-CoV-2 replication-transcription complex. Cell 182, 1560\u20131573.e13 (2020).","journal-title":"Cell"},{"key":"692_CR49","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2102516118","volume":"118","author":"B Malone","year":"2021","unstructured":"Malone, B. et al. Structural basis for backtracking by the SARS-CoV-2 replication\u2013transcription complex. Proc. Natl Acad. Sci. USA 118, e2102516118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"692_CR50","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25166-6","volume":"12","author":"JA Newman","year":"2021","unstructured":"Newman, J. A. et al. Structure, mechanism and crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase. Nat. Commun. 12, 4848 (2021).","journal-title":"Nat. Commun."},{"key":"692_CR51","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/jac\/dkq198","volume":"65","author":"K Chono","year":"2010","unstructured":"Chono, K. et al. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. J. Antimicrob. Chemother. 65, 1733\u20131741 (2010).","journal-title":"J. Antimicrob. Chemother."},{"key":"692_CR52","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nm0402-392","volume":"8","author":"G Kleymann","year":"2002","unstructured":"Kleymann, G. et al. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat. Med. 8, 392\u2013398 (2002).","journal-title":"Nat. Med."},{"key":"692_CR53","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nm0402-386","volume":"8","author":"JJ Crute","year":"2002","unstructured":"Crute, J. J. et al. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat. Med. 8, 386\u2013391 (2002).","journal-title":"Nat. Med."},{"key":"692_CR54","doi-asserted-by":"crossref","first-page":"eabf8711","DOI":"10.1126\/sciadv.abf8711","volume":"7","author":"M Schuller","year":"2021","unstructured":"Schuller, M. et al. Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking. Sci. Adv. 7, eabf8711 (2021).","journal-title":"Sci. Adv."},{"key":"692_CR55","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.tim.2017.11.011","volume":"26","author":"AR Fehr","year":"2018","unstructured":"Fehr, A. R., Jankevicius, G., Ahel, I. & Perlman, S. Viral macrodomains: unique mediators of viral replication and pathogenesis. Trends Microbiol. 26, 598\u2013610 (2018).","journal-title":"Trends Microbiol."},{"key":"692_CR56","doi-asserted-by":"crossref","first-page":"e01721-16","DOI":"10.1128\/mBio.01721-16","volume":"7","author":"AR Fehr","year":"2016","unstructured":"Fehr, A. R. et al. The conserved coronavirus macrodomain promotes virulence and suppresses the innate immune response during severe acute respiratory syndrome coronavirus infection. mBio 7, e01721-16 (2016).","journal-title":"mBio"},{"key":"692_CR57","doi-asserted-by":"crossref","first-page":"116788","DOI":"10.1016\/j.bmc.2022.116788","volume":"67","author":"LM Sherrill","year":"2022","unstructured":"Sherrill, L. M. et al. Design, synthesis and evaluation of inhibitors of the SARS-CoV-2 nsp3 macrodomain. Bioorg. Med. Chem. 67, 116788 (2022).","journal-title":"Bioorg. Med. Chem."},{"key":"692_CR58","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2212931120","volume":"120","author":"S Gahbauer","year":"2023","unstructured":"Gahbauer, S. et al. Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 macrodomain of SARS-CoV-2. Proc. Natl Acad. Sci. USA 120, e2212931120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"692_CR59","doi-asserted-by":"crossref","first-page":"105344","DOI":"10.1016\/j.antiviral.2022.105344","volume":"203","author":"A Roy","year":"2022","unstructured":"Roy, A. et al. Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening. Antiviral Res. 203, 105344 (2022).","journal-title":"Antiviral Res."},{"key":"692_CR60","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17495-9","volume":"11","author":"P Krafcikova","year":"2020","unstructured":"Krafcikova, P., Silhan, J., Nencka, R. & Boura, E. Structural analysis of the SARS-CoV-2 methyltransferase complex involved in RNA cap creation bound to sinefungin. Nat. Commun. 11, 3717 (2020).","journal-title":"Nat. Commun."},{"key":"692_CR61","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nature09489","volume":"468","author":"S Daffis","year":"2010","unstructured":"Daffis, S. et al. 2\u2019-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature 468, 452\u2013456 (2010).","journal-title":"Nature"},{"key":"692_CR62","doi-asserted-by":"crossref","first-page":"eabe1202","DOI":"10.1126\/scisignal.abe1202","volume":"13","author":"M Rosas-Lemus","year":"2020","unstructured":"Rosas-Lemus, M. et al. High-resolution structures of the SARS-CoV-2 2\u2019-O-methyltransferase reveal strategies for structure-based inhibitor design. Sci. Signal. 13, eabe1202 (2020).","journal-title":"Sci. Signal."},{"key":"692_CR63","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2100170118","volume":"118","author":"M Wilamowski","year":"2021","unstructured":"Wilamowski, M. et al. 2\u2019-O methylation of RNA cap in SARS-CoV-2 captured by serial crystallography. Proc. Natl Acad. Sci. USA 118, e2100170118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"692_CR64","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.1021\/acs.jmedchem.2c00120","volume":"65","author":"R Ahmed-Belkacem","year":"2022","unstructured":"Ahmed-Belkacem, R. et al. Potent Inhibition of SARS-CoV-2 nsp14 N7-methyltransferase by sulfonamide-based bisubstrate analogues. J. Med. Chem. 65, 6231\u20136249 (2022).","journal-title":"J. Med. Chem."},{"key":"692_CR65","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1021\/acsinfecdis.1c00131","volume":"7","author":"T Otava","year":"2021","unstructured":"Otava, T. et al. The structure-based design of SARS-CoV-2 nsp14 methyltransferase ligands yields nanomolar inhibitors. ACS Infect. Dis. 7, 2214\u20132220 (2021).","journal-title":"ACS Infect. Dis."},{"key":"692_CR66","doi-asserted-by":"crossref","first-page":"e01531-17","DOI":"10.1128\/JVI.01531-17","volume":"92","author":"JB Case","year":"2017","unstructured":"Case, J. B. et al. Murine hepatitis virus nsp14 exoribonuclease activity is required for resistance to innate immunity. J. Virol. 92, e01531-17 (2017).","journal-title":"J. Virol."},{"key":"692_CR67","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/pro.3873","volume":"29","author":"Y Kim","year":"2020","unstructured":"Kim, Y. et al. Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2. Protein Sci. 29, 1596\u20131605 (2020).","journal-title":"Protein Sci."},{"key":"692_CR68","doi-asserted-by":"crossref","first-page":"295","DOI":"10.4161\/rna.8.2.15196","volume":"8","author":"R Ulferts","year":"2011","unstructured":"Ulferts, R. & Ziebuhr, J. Nidovirus ribonucleases: structures and functions in viral replication. RNA Biol. 8, 295\u2013304 (2011).","journal-title":"RNA Biol."},{"key":"692_CR69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006195","volume":"13","author":"E Kindler","year":"2017","unstructured":"Kindler, E. et al. Early endonuclease-mediated evasion of RNA sensing ensures efficient coronavirus replication. PLoS Pathog. 13, e1006195 (2017).","journal-title":"PLoS Pathog."},{"key":"692_CR70","first-page":"E4251","volume":"114","author":"X Deng","year":"2017","unstructured":"Deng, X. et al. Coronavirus nonstructural protein 15 mediates evasion of dsRNA sensors and limits apoptosis in macrophages. Proc. Natl Acad. Sci. USA 114, E4251\u2013E4260 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"692_CR71","doi-asserted-by":"crossref","first-page":"8094","DOI":"10.1073\/pnas.1921485117","volume":"117","author":"M Hackbart","year":"2020","unstructured":"Hackbart, M., Deng, X. & Baker, S. C. Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors. Proc. Natl Acad. Sci. USA 117, 8094\u20138103 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"692_CR72","doi-asserted-by":"crossref","first-page":"12694","DOI":"10.1073\/pnas.0403127101","volume":"101","author":"KA Ivanov","year":"2004","unstructured":"Ivanov, K. A. et al. Major genetic marker of nidoviruses encodes a replicative endoribonuclease. Proc. Natl Acad. Sci. USA 101, 12694\u201312699 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"692_CR73","doi-asserted-by":"publisher","unstructured":"Godoy, A. S. et al. SARS-CoV-2 nidoviral RNA uridylate\u2010specific endoribonuclease (NSP15): a target enabling package https:\/\/doi.org\/10.5281\/zenodo.4452975 (2020).","DOI":"10.5281\/zenodo.4452975"},{"key":"692_CR74","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","volume":"379","author":"FG Hayden","year":"2018","unstructured":"Hayden, F. G. et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N. Engl. J. Med. 379, 913\u2013923 (2018).","journal-title":"N. Engl. J. Med."},{"key":"692_CR75","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/cid\/ciz908","volume":"71","author":"N Hirotsu","year":"2020","unstructured":"Hirotsu, N. et al. Baloxavir marboxil in Japanese pediatric patients with Influenza: safety and clinical and virologic outcomes. Clin. Infect. Dis. 71, 971\u2013981 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"692_CR76","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd4683","volume":"14","author":"K Katsuno","year":"2015","unstructured":"Katsuno, K. et al. Hit and lead criteria in drug discovery for infectious diseases of the developing world. Nat. Rev. Drug Discov. 14, 751\u2013758 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"692_CR77","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/psp4.12681","volume":"10","author":"X Zhang","year":"2021","unstructured":"Zhang, X. et al. Anti-SARS-CoV-2 repurposing drug database: clinical pharmacology considerations. CPT Pharmacomet. Syst. Pharm. 10, 973\u2013982 (2021).","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"key":"692_CR78","unstructured":"Highlights of prescribing information: TAMIFLU (oseltamivir phosphate). FDA https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021087s062lbl.pdf (2012)."},{"key":"692_CR79","doi-asserted-by":"crossref","first-page":"e537","DOI":"10.1093\/cid\/ciac481","volume":"76","author":"N Ranganath","year":"2023","unstructured":"Ranganath, N. et al. Rebound phenomenon after nirmatrelvir\/ritonavir treatment of coronavirus disease-2019 in high-risk persons. Clin. Infect. Dis. 76, e537\u2013e539 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"692_CR80","doi-asserted-by":"publisher","DOI":"10.1101\/2022.08.04.22278378","author":"EY Dai","year":"2022","unstructured":"Dai, E. Y. et al. Viral kinetics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron infection in mRNA-vaccinated individuals treated and not treated with nirmatrelvir\u2013ritonavir. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2022.08.04.22278378 (2022).","journal-title":"medRxiv"},{"key":"692_CR81","doi-asserted-by":"crossref","first-page":"n1648","DOI":"10.1136\/bmj.n1648","volume":"374","author":"H Crook","year":"2021","unstructured":"Crook, H., Raza, S., Nowell, J., Young, M. & Edison, P. Long covid \u2014 mechanisms, risk factors, and management. Br. Med. J. 374, n1648 (2021).","journal-title":"Br. Med. J."},{"key":"692_CR82","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s41591-022-01810-6","volume":"28","author":"J Choutka","year":"2022","unstructured":"Choutka, J., Jansari, V., Hornig, M. & Iwasaki, A. Unexplained post-acute infection syndromes. Nat. Med. 28, 911\u2013923 (2022).","journal-title":"Nat. Med."},{"key":"692_CR83","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41586-022-04569-5","volume":"604","author":"G Douaud","year":"2022","unstructured":"Douaud, G. et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature 604, 697\u2013707 (2022).","journal-title":"Nature"},{"key":"692_CR84","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.15.21251511","author":"GE Serrano","year":"2021","unstructured":"Serrano, G. E. et al. Mapping of SARS-CoV-2 brain invasion and histopathology in COVID-19 disease. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.02.15.21251511 (2021).","journal-title":"medRxiv"},{"key":"692_CR85","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S0140-6736(05)74775-9","volume":"355","author":"TN Raju","year":"2000","unstructured":"Raju, T. N. The Nobel chronicles. 1988: James Whyte Black (b 1924), Gertrude Elion (1918\u201399), and George H Hitchings (1905\u201398). Lancet 355, 1022 (2000).","journal-title":"Lancet"},{"key":"692_CR86","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1128\/AAC.43.10.2444","volume":"43","author":"AK Patick","year":"1999","unstructured":"Patick, A. K. et al. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 43, 2444\u20132450 (1999).","journal-title":"Antimicrob. Agents Chemother."},{"key":"692_CR87","doi-asserted-by":"crossref","first-page":"128384","DOI":"10.1016\/j.bmcl.2021.128384","volume":"52","author":"H Kai","year":"2021","unstructured":"Kai, H. et al. Discovery of clinical candidate Sivopixant (S-600918): lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists. Bioorg. Med. Chem. Lett. 52, 128384 (2021).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"692_CR88","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1039\/D1MD00228G","volume":"13","author":"S M\u00fcller","year":"2022","unstructured":"M\u00fcller, S. et al. Target 2035 - update on the quest for a probe for every protein. RSC Med. Chem. 13, 13\u201321 (2022).","journal-title":"RSC Med. Chem."},{"key":"692_CR89","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-18709-w","volume":"11","author":"A Douangamath","year":"2020","unstructured":"Douangamath, A. et al. Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease. Nat. Commun. 11, 5047 (2020).","journal-title":"Nat. Commun."},{"key":"692_CR90","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41557-020-0496-2","volume":"12","author":"J Chodera","year":"2020","unstructured":"Chodera, J., Lee, A. A., London, N. & von Delft, F. Crowdsourcing drug discovery for pandemics. Nat. Chem. 12, 581 (2020).","journal-title":"Nat. Chem."},{"key":"692_CR91","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1021\/jacs.1c08402","volume":"144","author":"A Luttens","year":"2022","unstructured":"Luttens, A. et al. Ultralarge virtual screening identifies SARS-CoV-2 main protease inhibitors with broad-spectrum activity against coronaviruses. J. Am. Chem. Soc. 144, 2905\u20132920 (2022).","journal-title":"J. Am. Chem. Soc."},{"key":"692_CR92","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1021\/acscentsci.1c00039","volume":"7","author":"C-H Zhang","year":"2021","unstructured":"Zhang, C.-H. et al. Potent noncovalent inhibitors of the main protease of SARS-CoV-2 from molecular sculpting of the drug perampanel guided by free energy perturbation calculations. ACS Cent. Sci. 7, 467\u2013475 (2021).","journal-title":"ACS Cent. Sci."},{"key":"692_CR93","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1073\/pnas.0306446101","volume":"101","author":"G Simmons","year":"2004","unstructured":"Simmons, G. et al. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc. Natl Acad. Sci. USA 101, 4240\u20134245 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"692_CR94","doi-asserted-by":"crossref","first-page":"107940","DOI":"10.1016\/j.celrep.2020.107940","volume":"32","author":"AJ Pruijssers","year":"2020","unstructured":"Pruijssers, A. J. et al. Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Cell Rep. 32, 107940 (2020).","journal-title":"Cell Rep."},{"key":"692_CR95","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1099\/jgv.0.001453","volume":"101","author":"NS Ogando","year":"2020","unstructured":"Ogando, N. S. et al. SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology. J. Gen. Virol. 101, 925\u2013940 (2020).","journal-title":"J. Gen. Virol."},{"key":"692_CR96","volume":"17","author":"M Sasaki","year":"2021","unstructured":"Sasaki, M. et al. SARS-CoV-2 variants with mutations at the S1\/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells. PLoS Pathog. 17, e1009233 (2021).","journal-title":"PLoS Pathog."},{"key":"692_CR97","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-020-00763-0","volume":"12","author":"AD Davidson","year":"2020","unstructured":"Davidson, A. D. et al. Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein. Genome Med. 12, 68 (2020).","journal-title":"Genome Med."},{"key":"692_CR98","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.virs.2022.01.029","volume":"37","author":"ST Sonnleitner","year":"2022","unstructured":"Sonnleitner, S. T. et al. The mutational dynamics of the SARS-CoV-2 virus in serial passages in vitro. Virol. Sin. 37, 198\u2013207 (2022).","journal-title":"Virol. Sin."},{"key":"692_CR99","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41586-022-04482-x","volume":"604","author":"DC Schultz","year":"2022","unstructured":"Schultz, D. C. et al. Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2. Nature 604, 134\u2013140 (2022).","journal-title":"Nature"},{"key":"692_CR100","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2666-5247(20)30004-5","volume":"1","author":"H Chu","year":"2020","unstructured":"Chu, H. et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. Lancet Microbe 1, e14\u2013e23 (2020). Key publication assessing SARS-CoV-2 cellular susceptibility and transmissibility for laboratory studies, in comparison with SARS-CoV.","journal-title":"Lancet Microbe"},{"key":"692_CR101","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733 (2020).","journal-title":"N. Engl. J. Med."},{"key":"692_CR102","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3390\/v14071369","volume":"14","author":"C-W Chang","year":"2022","unstructured":"Chang, C.-W. et al. A newly engineered A549 cell line expressing ACE2 and TMPRSS2 is highly permissive to SARS-CoV-2, including the Delta and Omicron variants. Viruses 14, 1369 (2022).","journal-title":"Viruses"},{"key":"692_CR103","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bbrc.2021.09.015","volume":"577","author":"M Sasaki","year":"2021","unstructured":"Sasaki, M. et al. Air-liquid interphase culture confers SARS-CoV-2 susceptibility to A549 alveolar epithelial cells. Biochem. Biophys. Res. Commun. 577, 146\u2013151 (2021).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"692_CR104","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","volume":"117","author":"J Shang","year":"2020","unstructured":"Shang, J. et al. Cell entry mechanisms of SARS-CoV-2. Proc. Natl Acad. Sci. USA 117, 11727\u201311734 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"692_CR105","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.bbrc.2004.07.060","volume":"321","author":"Y Nie","year":"2004","unstructured":"Nie, Y. et al. Highly infectious SARS-CoV pseudotyped virus reveals the cell tropism and its correlation with receptor expression. Biochem. Biophys. Res. Commun. 321, 994\u20131000 (2004).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"692_CR106","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41586-021-03925-1","volume":"598","author":"FA Lempp","year":"2021","unstructured":"Lempp, F. A. et al. Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. Nature 598, 342\u2013347 (2021).","journal-title":"Nature"},{"key":"692_CR107","doi-asserted-by":"crossref","first-page":"L462","DOI":"10.1152\/ajplung.00397.2021","volume":"322","author":"R Wang","year":"2022","unstructured":"Wang, R. et al. Human airway lineages derived from pluripotent stem cells reveal the epithelial responses to SARS-CoV-2 infection. Am. J. Physiol. Lung Cell Mol. Physiol. 322, L462\u2013L478 (2022).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"692_CR108","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/s41385-020-00370-7","volume":"14","author":"JD Davis","year":"2021","unstructured":"Davis, J. D. & Wypych, T. P. Cellular and functional heterogeneity of the airway epithelium. Mucosal Immunol. 14, 978\u2013990 (2021).","journal-title":"Mucosal Immunol."},{"key":"692_CR109","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.virusres.2007.03.013","volume":"133","author":"AC Sims","year":"2008","unstructured":"Sims, A. C., Burkett, S. E., Yount, B. & Pickles, R. J. SARS-CoV replication and pathogenesis in an in vitro model of the human conducting airway epithelium. Virus Res 133, 33\u201344 (2008).","journal-title":"Virus Res"},{"key":"692_CR110","unstructured":"FDA. Emergency use authorization for paxlovid: CDER Review, https:\/\/www.fda.gov\/media\/155194\/download (2021)."},{"key":"692_CR111","doi-asserted-by":"crossref","first-page":"105122","DOI":"10.1016\/j.antiviral.2021.105122","volume":"192","author":"TND Do","year":"2021","unstructured":"Do, T. N. D. et al. A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents. Antiviral Res. 192, 105122 (2021). A key example of SARS-CoV-2 replication in primary human epithelial cells.","journal-title":"Antiviral Res."},{"key":"692_CR112","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-28354-0","volume":"13","author":"R Abdelnabi","year":"2022","unstructured":"Abdelnabi, R. et al. The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern. Nat. Commun. 13, 719 (2022).","journal-title":"Nat. Commun."},{"key":"692_CR113","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36735-z","volume":"9","author":"RE Rayner","year":"2019","unstructured":"Rayner, R. E., Makena, P., Prasad, G. L. & Cormet-Boyaka, E. Optimization of normal human bronchial epithelial (NHBE) cell 3D cultures for in vitro lung model studies. Sci. Rep. 9, 500 (2019).","journal-title":"Sci. Rep."},{"key":"692_CR114","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tiv.2017.11.005","volume":"47","author":"PS Hiemstra","year":"2018","unstructured":"Hiemstra, P. S., Grootaers, G., van der Does, A. M., Krul, C. A. M. & Kooter, I. M. Human lung epithelial cell cultures for analysis of inhaled toxicants: Lessons learned and future directions. Toxicol. Vitr. 47, 137\u2013146 (2018).","journal-title":"Toxicol. Vitr."},{"key":"692_CR115","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.stem.2021.12.010","volume":"29","author":"J Jansen","year":"2022","unstructured":"Jansen, J. et al. SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids. Cell Stem Cell 29, 217\u2013231.e8 (2022).","journal-title":"Cell Stem Cell"},{"key":"692_CR116","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1021\/jm401401n","volume":"57","author":"V Lohmann","year":"2014","unstructured":"Lohmann, V. & Bartenschlager, R. On the history of hepatitis C virus cell culture systems. J. Med. Chem. 57, 1627\u20131642 (2014).","journal-title":"J. Med. Chem."},{"key":"692_CR117","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41586-022-04479-6","volume":"603","author":"KPY Hui","year":"2022","unstructured":"Hui, K. P. Y. et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature 603, 715\u2013720 (2022). Demonstrates differential pathogenicity of the Delta and Omicron variants in cell culture.","journal-title":"Nature"},{"key":"692_CR118","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12985-022-01802-5","volume":"19","author":"L Mautner","year":"2022","unstructured":"Mautner, L. et al. Replication kinetics and infectivity of SARS-CoV-2 variants of concern in common cell culture models. Virol. J. 19, 76 (2022).","journal-title":"Virol. J."},{"key":"692_CR119","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41586-022-04474-x","volume":"603","author":"B Meng","year":"2022","unstructured":"Meng, B. et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature 603, 706\u2013714 (2022).","journal-title":"Nature"},{"key":"692_CR120","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00097-21","volume":"65","author":"S Ramirez","year":"2021","unstructured":"Ramirez, S. et al. Overcoming culture restriction for SARS-CoV-2 in human cells facilitates the screening of compounds inhibiting viral replication. Antimicrob. Agents Chemother. 65, e0009721 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"692_CR121","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.chom.2020.04.004","volume":"27","author":"X Xie","year":"2020","unstructured":"Xie, X. et al. An infectious cDNA clone of SARS-CoV-2. Cell Host Microbe 27, 841\u2013848.e3 (2020).","journal-title":"Cell Host Microbe"},{"key":"692_CR122","volume":"11","author":"X Xie","year":"2020","unstructured":"Xie, X. et al. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. Nat. Commun. 11, 5214 (2020).","journal-title":"Nat. Commun."},{"key":"692_CR123","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17892-0","volume":"11","author":"AE Muruato","year":"2020","unstructured":"Muruato, A. E. et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat. Commun. 11, 4059 (2020).","journal-title":"Nat. Commun."},{"key":"692_CR124","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","volume":"285","author":"V Lohmann","year":"1999","unstructured":"Lohmann, V. et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110\u2013113 (1999).","journal-title":"Science"},{"key":"692_CR125","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.drudis.2020.03.010","volume":"25","author":"H Hannemann","year":"2020","unstructured":"Hannemann, H. Viral replicons as valuable tools for drug discovery. Drug. Discov. Today 25, 1026\u20131033 (2020).","journal-title":"Drug. Discov. Today"},{"key":"692_CR126","doi-asserted-by":"crossref","first-page":"e01316-17","DOI":"10.1128\/JVI.01316-17","volume":"91","author":"W Tao","year":"2017","unstructured":"Tao, W., Gan, T., Guo, M., Xu, Y. & Zhong, J. Novel stable Ebola virus minigenome replicon reveals remarkable stability of the viral genome. J. Virol. 91, e01316-17 (2017).","journal-title":"J. Virol."},{"key":"692_CR127","volume":"118","author":"X He","year":"2021","unstructured":"He, X. et al. Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing. Proc. Natl Acad. Sci. USA 118, e2025866118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"692_CR128","volume":"11","author":"T Kotaki","year":"2021","unstructured":"Kotaki, T., Xie, X., Shi, P.-Y. & Kameoka, M. A. PCR amplicon-based SARS-CoV-2 replicon for antiviral evaluation. Sci. Rep. 11, 2229 (2021).","journal-title":"Sci. Rep."},{"key":"692_CR129","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1126\/science.abj8430","volume":"374","author":"I Ricardo-Lax","year":"2021","unstructured":"Ricardo-Lax, I. et al. Replication and single-cycle delivery of SARS-CoV-2 replicons. Science 374, 1099\u20131106 (2021).","journal-title":"Science"},{"key":"692_CR130","doi-asserted-by":"crossref","first-page":"108234","DOI":"10.1016\/j.celrep.2020.108234","volume":"33","author":"H Xia","year":"2020","unstructured":"Xia, H. et al. Evasion of type I interferon by SARS-CoV-2. Cell Rep. 33, 108234 (2020).","journal-title":"Cell Rep."},{"key":"692_CR131","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.cell.2021.02.044","volume":"184","author":"X Zhang","year":"2021","unstructured":"Zhang, X. et al. A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence. Cell 184, 2229\u20132238.e13 (2021).","journal-title":"Cell"},{"key":"692_CR132","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions. Nat. Commun. 13, 4337 (2022).","journal-title":"Nat. Commun."},{"key":"692_CR133","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1002\/jmv.27683","volume":"94","author":"W Chiu","year":"2022","unstructured":"Chiu, W. et al. Development and optimization of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures. J. Med. Virol. 94, 3101\u20133111 (2022).","journal-title":"J. Med. Virol."},{"key":"692_CR134","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23328-0","volume":"12","author":"MA Bakowski","year":"2021","unstructured":"Bakowski, M. A. et al. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. Nat. Commun. 12, 3309 (2021).","journal-title":"Nat. Commun."},{"key":"692_CR135","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41592-022-01447-w","volume":"19","author":"H Chu","year":"2022","unstructured":"Chu, H., Chan, J. F.-W. & Yuen, K.-Y. Animal models in SARS-CoV-2 research. Nat. Methods 19, 392\u2013394 (2022).","journal-title":"Nat. Methods"},{"key":"692_CR136","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.coviro.2021.06.007","volume":"50","author":"RD de Vries","year":"2021","unstructured":"de Vries, R. D. et al. Animal models of SARS-CoV-2 transmission. Curr. Opin. Virol. 50, 8\u201316 (2021).","journal-title":"Curr. Opin. Virol."},{"key":"692_CR137","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.virol.2007.12.032","volume":"374","author":"Y-K Chu","year":"2008","unstructured":"Chu, Y.-K. et al. The SARS-CoV ferret model in an infection-challenge study. Virology 374, 151\u2013163 (2008).","journal-title":"Virology"},{"key":"692_CR138","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/j.vaccine.2005.01.033","volume":"23","author":"M Czub","year":"2005","unstructured":"Czub, M., Weingartl, H., Czub, S., He, R. & Cao, J. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine 23, 2273\u20132279 (2005).","journal-title":"Vaccine"},{"key":"692_CR139","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1126\/science.abb7015","volume":"368","author":"J Shi","year":"2020","unstructured":"Shi, J. et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science 368, 1016\u20131020 (2020). Experimental overview on susceptibility of various animal species to SARS-CoV-2 infection.","journal-title":"Science"},{"key":"692_CR140","volume":"12","author":"KA Ryan","year":"2021","unstructured":"Ryan, K. A. et al. Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity. Nat. Commun. 12, 81 (2021).","journal-title":"Nat. Commun."},{"key":"692_CR141","doi-asserted-by":"crossref","first-page":"16587","DOI":"10.1073\/pnas.2009799117","volume":"117","author":"M Imai","year":"2020","unstructured":"Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl Acad. Sci. USA 117, 16587\u201316595 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"692_CR142","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/cid\/ciaa325","volume":"71","author":"JF-W Chan","year":"2020","unstructured":"Chan, J. F.-W. et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden syrian hamster model: implications for disease pathogenesis and transmissibility. Clin. Infect. Dis. 71, 2428\u20132446 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"692_CR143","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41586-020-2312-y","volume":"583","author":"L Bao","year":"2020","unstructured":"Bao, L. et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583, 830\u2013833 (2020).","journal-title":"Nature"},{"key":"692_CR144","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41586-020-2708-8","volume":"586","author":"KH Dinnon 3rd","year":"2020","unstructured":"Dinnon, K. H. 3rd et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature 586, 560\u2013566 (2020). A commonly used animal SARS-CoV-2 model.","journal-title":"Nature"},{"key":"692_CR145","doi-asserted-by":"crossref","first-page":"103643","DOI":"10.1016\/j.ebiom.2021.103643","volume":"73","author":"H Shuai","year":"2021","unstructured":"Shuai, H. et al. Emerging SARS-CoV-2 variants expand species tropism to murines. eBioMedicine 73, 103643 (2021).","journal-title":"eBioMedicine"},{"key":"692_CR146","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010161","volume":"18","author":"C Mu\u00f1oz-Fontela","year":"2022","unstructured":"Mu\u00f1oz-Fontela, C. et al. Advances and gaps in SARS-CoV-2 infection models. PLoS Pathog. 18, e1010161 (2022).","journal-title":"PLoS Pathog."},{"key":"692_CR147","doi-asserted-by":"crossref","first-page":"eabj3627","DOI":"10.1126\/sciadv.abj3627","volume":"7","author":"VJ Munster","year":"2021","unstructured":"Munster, V. J. et al. Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques. Sci. Adv. 7, eabj3627 (2021).","journal-title":"Sci. Adv."},{"key":"692_CR148","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.medj.2022.03.004","volume":"3","author":"K McMahan","year":"2022","unstructured":"McMahan, K. et al. Reduced pathogenicity of the SARS-CoV-2 Omicron variant in hamsters. Med 3, 262\u2013268.e4 (2022).","journal-title":"Med"},{"key":"692_CR149","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41392-022-00930-2","volume":"7","author":"Y-N Zhang","year":"2022","unstructured":"Zhang, Y.-N. et al. Different pathogenesis of SARS-CoV-2 Omicron variant in wild-type laboratory mice and hamsters. Signal Transduct. Target. Ther. 7, 62 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"692_CR150","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1080\/22221751.2022.2095932","volume":"11","author":"M Rissmann","year":"2022","unstructured":"Rissmann, M. et al. Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters. Emerg. Microbes Infect. 11, 1778\u20131786 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"692_CR151","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3390\/v14061139","volume":"14","author":"JP Natekar","year":"2022","unstructured":"Natekar, J. P. et al. Differential pathogenesis of SARS-CoV-2 variants of concern in human ACE2-expressing mice. Viruses\u00a014, 1139 (2022).","journal-title":"Viruses"},{"key":"692_CR152","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41586-022-04441-6","volume":"603","author":"PJ Halfmann","year":"2022","unstructured":"Halfmann, P. J. et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature 603, 687\u2013692 (2022).","journal-title":"Nature"},{"key":"692_CR153","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.00139-22","volume":"60","author":"AM Laitman","year":"2022","unstructured":"Laitman, A. M. et al. The SARS-CoV-2 Omicron variant does not have higher nasal viral loads compared to the Delta variant in symptomatic and asymptomatic individuals. J. Clin. Microbiol. 60, e0013922 (2022).","journal-title":"J. Clin. Microbiol."},{"key":"692_CR154","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/s41591-022-01816-0","volume":"28","author":"O Puhach","year":"2022","unstructured":"Puhach, O. et al. Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2. Nat. Med. 28, 1491\u20131500 (2022).","journal-title":"Nat. Med."},{"key":"692_CR155","first-page":"eabq40","volume":"15","author":"M Sasaki","year":"2022","unstructured":"Sasaki, M. et al. S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters. Sci. Transl. Med. 15, eabq40 (2022).","journal-title":"Sci. Transl. Med."},{"key":"692_CR156","doi-asserted-by":"crossref","first-page":"eabo5070","DOI":"10.1126\/scitranslmed.abo5070","volume":"14","author":"KH Dinnon 3rd","year":"2022","unstructured":"Dinnon, K. H. 3rd et al. SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice. Sci. Transl. Med. 14, eabo5070 (2022).","journal-title":"Sci. Transl. Med."},{"key":"692_CR157","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrmicro2129","volume":"7","author":"NJ Sullivan","year":"2009","unstructured":"Sullivan, N. J., Martin, J. E., Graham, B. S. & Nabel, G. J. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat. Rev. Microbiol. 7, 393\u2013400 (2009).","journal-title":"Nat. Rev. Microbiol."},{"key":"692_CR158","volume":"1","author":"DWC Beasley","year":"2016","unstructured":"Beasley, D. W. C., Brasel, T. L. & Comer, J. E. First vaccine approval under the FDA animal rule. NPJ Vaccines 1, 16013 (2016).","journal-title":"NPJ Vaccines"},{"key":"692_CR159","unstructured":"FDA. Product Development under the Animal Rule: Guidance for Industry (Center for Drug Evaluation and Research, 2015)."},{"key":"692_CR160","unstructured":"Animal rule approvals. FDA https:\/\/www.fda.gov\/drugs\/nda-and-bla-approvals\/animal-rule-approvals (2021)."},{"key":"692_CR161","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/v12070779","volume":"12","author":"N Osterrieder","year":"2020","unstructured":"Osterrieder, N. et al. Age-dependent progression of SARS-CoV-2 infection in Syrian hamsters. Viruses 12, 779 (2020).","journal-title":"Viruses"},{"key":"692_CR162","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/s41587-021-01155-4","volume":"40","author":"E Sefik","year":"2022","unstructured":"Sefik, E. et al. A humanized mouse model of chronic COVID-19. Nat. Biotechnol. 40, 906\u2013920 (2022).","journal-title":"Nat. Biotechnol."},{"key":"692_CR163","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S2468-1253(22)00166-2","volume":"7","author":"P Brodin","year":"2022","unstructured":"Brodin, P. & Arditi, M. Severe acute hepatitis in children: investigate SARS-CoV-2 superantigens. Lancet Gastroenterol. Hepatol. 7, 594\u2013596 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"692_CR164","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12931-018-0784-1","volume":"19","author":"R Lambkin-Williams","year":"2018","unstructured":"Lambkin-Williams, R., Noulin, N., Mann, A., Catchpole, A. & Gilbert, A. S. The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics. Respir. Res 19, 123 (2018).","journal-title":"Respir. Res"},{"key":"692_CR165","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJMp2106970","volume":"385","author":"G Rapeport","year":"2021","unstructured":"Rapeport, G. et al. SARS-CoV-2 human challenge studies - establishing the model during an evolving pandemic. N. Engl. J. Med. 385, 961\u2013964 (2021).","journal-title":"N. Engl. J. Med."},{"key":"692_CR166","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/s41591-022-01780-9","volume":"28","author":"B Killingley","year":"2022","unstructured":"Killingley, B. et al. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. Nat. Med. 28, 1031\u20131041 (2022).","journal-title":"Nat. Med."},{"key":"692_CR167","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41591-020-0869-5","volume":"26","author":"X He","year":"2020","unstructured":"He, X. et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat. Med. 26, 672\u2013675 (2020). Discusses the temporal dynamics of viral shedding, with implications for viral kinetics and transmissibility.","journal-title":"Nat. Med."},{"key":"692_CR168","doi-asserted-by":"crossref","first-page":"e01884-19","DOI":"10.1128\/AAC.01884-19","volume":"64","author":"J DeVincenzo","year":"2020","unstructured":"DeVincenzo, J. et al. A randomized, placebo-controlled, respiratory syncytial virus human challenge study of the antiviral efficacy, safety, and pharmacokinetics of RV521, an inhibitor of the RSV-F protein. Antimicrob. Agents Chemother. 64, e01884-19 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"692_CR169","doi-asserted-by":"crossref","DOI":"10.1038\/srep38749","volume":"6","author":"L Canini","year":"2016","unstructured":"Canini, L., Woolhouse, M. E. J., Maines, T. R. & Carrat, F. Heterogeneous shedding of influenza by human subjects and its implications for epidemiology and control. Sci. Rep. 6, 38749 (2016).","journal-title":"Sci. Rep."},{"key":"692_CR170","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1128\/AAC.00905-07","volume":"51","author":"SL Binford","year":"2007","unstructured":"Binford, S. L. et al. In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 51, 4366\u20134373 (2007).","journal-title":"Antimicrob. Agents Chemother."},{"key":"692_CR171","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1056\/NEJMp058291","volume":"353","author":"A Moscona","year":"2005","unstructured":"Moscona, A. Oseltamivir resistance\u2013disabling our influenza defenses. N. Engl. J. Med. 353, 2633\u20132636 (2005).","journal-title":"N. Engl. J. Med."},{"key":"692_CR172","first-page":"337","volume":"221","author":"LV Gubareva","year":"2020","unstructured":"Gubareva, L. V. & Fry, A. M. Baloxavir and treatment-emergent resistance: public health insights and next steps. J. Infect. Dis. 221, 337\u2013339 (2020).","journal-title":"J. Infect. Dis."},{"key":"692_CR173","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.idc.2010.01.001","volume":"24","author":"L Strasfeld","year":"2010","unstructured":"Strasfeld, L. & Chou, S. Antiviral drug resistance: mechanisms and clinical implications. Infect. Dis. Clin. North Am. 24, 413\u2013437 (2010).","journal-title":"Infect. Dis. Clin. North Am."},{"key":"692_CR174","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jhep.2010.01.041","volume":"53","author":"U Chatterji","year":"2010","unstructured":"Chatterji, U. et al. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J. Hepatol. 53, 50\u201356 (2010).","journal-title":"J. Hepatol."},{"key":"692_CR175","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1128\/JVI.01863-12","volume":"87","author":"AN Ratcliff","year":"2013","unstructured":"Ratcliff, A. N., Shi, W. & Arts, E. J. HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120. J. Virol. 87, 923\u2013934 (2013).","journal-title":"J. Virol."},{"key":"692_CR176","doi-asserted-by":"crossref","DOI":"10.1186\/1742-4690-10-43","volume":"10","author":"M Roche","year":"2013","unstructured":"Roche, M. et al. A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations. Retrovirology 10, 43 (2013).","journal-title":"Retrovirology"},{"key":"692_CR177","doi-asserted-by":"crossref","first-page":"104353","DOI":"10.1016\/j.meegid.2020.104353","volume":"83","author":"R Cagliani","year":"2020","unstructured":"Cagliani, R., Forni, D., Clerici, M. & Sironi, M. Coding potential and sequence conservation of SARS-CoV-2 and related animal viruses. Infect. Genet. Evol. 83, 104353 (2020).","journal-title":"Infect. Genet. Evol."},{"key":"692_CR178","doi-asserted-by":"crossref","first-page":"117693432110141","DOI":"10.1177\/11769343211014167","volume":"17","author":"SP Ryder","year":"2021","unstructured":"Ryder, S. P., Morgan, B. R., Coskun, P., Antkowiak, K. & Massi, F. Analysis of emerging variants in structured regions of the SARS-CoV-2 genome. Evol. Bioinform. Online 17, 11769343211014167 (2021).","journal-title":"Evol. Bioinform. Online"},{"key":"692_CR179","doi-asserted-by":"crossref","first-page":"e00754-20","DOI":"10.1128\/mSphere.00754-20","volume":"5","author":"AP Chan","year":"2020","unstructured":"Chan, A. P., Choi, Y. & Schork, N. J. Conserved genomic terminals of SARS-CoV-2 as coevolving functional elements and potential therapeutic targets. mSphere 5, e00754-20 (2020).","journal-title":"mSphere"},{"key":"692_CR180","doi-asserted-by":"crossref","first-page":"104597","DOI":"10.1016\/j.antiviral.2019.104597","volume":"171","author":"GR Painter","year":"2019","unstructured":"Painter, G. R. et al. The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection. Antiviral Res. 171, 104597 (2019).","journal-title":"Antiviral Res."},{"key":"692_CR181","doi-asserted-by":"crossref","first-page":"eabg0821","DOI":"10.1126\/science.abg0821","volume":"372","author":"KA Lythgoe","year":"2021","unstructured":"Lythgoe, K. A. et al. SARS-CoV-2 within-host diversity and transmission. Science 372, eabg0821 (2021).","journal-title":"Science"},{"key":"692_CR182","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0966-842X(99)01590-5","volume":"7","author":"X Forns","year":"1999","unstructured":"Forns, X., Purcell, R. H. & Bukh, J. Quasispecies in viral persistence and pathogenesis of hepatitis C virus. Trends Microbiol 7, 402\u2013410 (1999).","journal-title":"Trends Microbiol"},{"key":"692_CR183","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007167","volume":"14","author":"J Raghwani","year":"2018","unstructured":"Raghwani, J. et al. Evolution of HIV-1 within untreated individuals and at the population scale in Uganda. PLoS Pathog. 14, e1007167 (2018).","journal-title":"PLoS Pathog."},{"key":"692_CR184","volume":"7","author":"JP Barton","year":"2016","unstructured":"Barton, J. P. et al. Relative rate and location of intra-host HIV evolution to evade cellular immunity are predictable. Nat. Commun. 7, 11660 (2016).","journal-title":"Nat. Commun."},{"key":"692_CR185","doi-asserted-by":"crossref","first-page":"20509","DOI":"10.1073\/pnas.1105797108","volume":"108","author":"MH Powdrill","year":"2011","unstructured":"Powdrill, M. H. et al. Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc. Natl Acad. Sci. USA 108, 20509\u201320513 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"692_CR186","doi-asserted-by":"crossref","first-page":"24614","DOI":"10.1073\/pnas.2017726117","volume":"117","author":"JW Rausch","year":"2020","unstructured":"Rausch, J. W., Capoferri, A. A., Katusiime, M. G., Patro, S. C. & Kearney, M. F. Low genetic diversity may be an Achilles heel of SARS-CoV-2. Proc. Natl Acad. Sci. USA 117, 24614\u201324616 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"692_CR187","doi-asserted-by":"crossref","first-page":"106210","DOI":"10.1016\/j.isci.2023.106210","volume":"26","author":"K Takada","year":"2023","unstructured":"Takada, K. et al. Genomic diversity of SARS-CoV-2 can be accelerated by a mutation in the nsp14 gene. iScience 26,\u00a0106210 (2023).","journal-title":"iScience"},{"key":"692_CR188","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000896","volume":"6","author":"LD Eckerle","year":"2010","unstructured":"Eckerle, L. D. et al. Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. PLoS Pathog. 6, e1000896 (2010).","journal-title":"PLoS Pathog."},{"key":"692_CR189","volume":"9","author":"EC Smith","year":"2013","unstructured":"Smith, E. C., Blanc, H., Surdel, M. C., Vignuzzi, M. & Denison, M. R. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog. 9, e1003565 (2013).","journal-title":"PLoS Pathog."},{"key":"692_CR190","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2147\/IDR.S156581","volume":"11","author":"D Bonsall","year":"2018","unstructured":"Bonsall, D. et al. Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse. Infect. Drug Resist. 11, 1119\u20131135 (2018).","journal-title":"Infect. Drug Resist."},{"key":"692_CR191","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/jama.2009.294","volume":"301","author":"NJ Dharan","year":"2009","unstructured":"Dharan, N. J. et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. J. Am. Med. Assoc. 301, 1034\u20131041 (2009).","journal-title":"J. Am. Med. Assoc."},{"key":"692_CR192","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3201\/eid1502.081031","volume":"15","author":"SH Hauge","year":"2009","unstructured":"Hauge, S. H., Dudman, S., Borgen, K., Lackenby, A. & Hungnes, O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg. Infect. Dis. 15, 155\u2013162 (2009).","journal-title":"Emerg. Infect. Dis."},{"key":"692_CR193","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41564-019-0609-0","volume":"5","author":"M Imai","year":"2020","unstructured":"Imai, M. et al. Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets. Nat. Microbiol. 5, 27\u201333 (2020).","journal-title":"Nat. Microbiol."},{"key":"692_CR194","volume":"17","author":"LY Lee","year":"2021","unstructured":"Lee, L. Y. et al. Evaluating the fitness of PA\/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model. PLoS Pathog. 17, e1009527 (2021).","journal-title":"PLoS Pathog."},{"key":"692_CR195","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jiac.2019.12.002","volume":"26","author":"H Ikematsu","year":"2020","unstructured":"Ikematsu, H. et al. Duration of fever and PA\/I38X-substituted virus emergence in patients treated with baloxavir in the 2018-2019 influenza season. J. Infect. Chemother. 26, 400\u2013402 (2020).","journal-title":"J. Infect. Chemother."},{"key":"692_CR196","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-29104-y","volume":"13","author":"S Gandhi","year":"2022","unstructured":"Gandhi, S. et al. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nat. Commun. 13, 1547 (2022).","journal-title":"Nat. Commun."},{"key":"692_CR197","doi-asserted-by":"crossref","first-page":"e4020","DOI":"10.1093\/cid\/ciaa1637","volume":"73","author":"J Malsy","year":"2021","unstructured":"Malsy, J. et al. Sustained response after remdesivir and convalescent plasma therapy in a B-cell-depleted patient with protracted coronavirus disease 2019 (COVID-19). Clin. Infect. Dis. 73, e4020\u2013e4024 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"692_CR198","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1093\/infdis\/jiaa446","volume":"222","author":"M Helleberg","year":"2020","unstructured":"Helleberg, M. et al. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J. Infect. Dis. 222, 1103\u20131107 (2020).","journal-title":"J. Infect. Dis."},{"key":"692_CR199","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","volume":"401","author":"CC Butler","year":"2023","unstructured":"Butler, C. C. et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet 401, 281\u2013293 (2023).","journal-title":"Lancet"},{"key":"692_CR200","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1093\/infdis\/jis761","volume":"207","author":"DL Wyles","year":"2013","unstructured":"Wyles, D. L. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J. Infect. Dis. 207, S33\u2013S39 (2013).","journal-title":"J. Infect. Dis."},{"key":"692_CR201","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1128\/AAC.00834-07","volume":"52","author":"ST Shi","year":"2008","unstructured":"Shi, S. T. et al. In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother. 52, 675\u2013683 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"692_CR202","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-27890-4","volume":"8","author":"S Omoto","year":"2018","unstructured":"Omoto, S. et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci. Rep. 8, 9633 (2018).","journal-title":"Sci. Rep."},{"key":"692_CR203","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1021\/acs.chemrev.0c00648","volume":"121","author":"AN Matthew","year":"2021","unstructured":"Matthew, A. N. et al. Drug design strategies to avoid resistance in direct-acting antivirals and beyond. Chem. Rev. 121, 3238\u20133270 (2021). Discusses the concept of a substrate envelope for directly acting antivirals.","journal-title":"Chem. Rev."},{"key":"692_CR204","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0969-2126(02)00720-7","volume":"10","author":"M Prabu-Jeyabalan","year":"2002","unstructured":"Prabu-Jeyabalan, M., Nalivaika, E. & Schiffer, C. A. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 10, 369\u2013381 (2002).","journal-title":"Structure"},{"key":"692_CR205","unstructured":"Discovery and Development of PBI-0451. A novel oral protease inhibitor for the potential treatment of SARS-CoV-2. Pardes Biosciences https:\/\/ir.pardesbio.com\/static-files\/fc7c4f8c-e0bd-4b97-8c9c-eff09bafd4db (2022)."},{"key":"692_CR206","first-page":"1333","volume":"11","author":"NM King","year":"2004","unstructured":"King, N. M., Prabu-Jeyabalan, M., Nalivaika, E. A. & Schiffer, C. A. Combating susceptibility to drug resistance: lessons from HIV-1 protease. Chem. Biol. 11, 1333\u20131338 (2004).","journal-title":"Chem. Biol."},{"key":"692_CR207","doi-asserted-by":"crossref","first-page":"20986","DOI":"10.1073\/pnas.1006370107","volume":"107","author":"KP Romano","year":"2010","unstructured":"Romano, K. P., Ali, A., Royer, W. E. & Schiffer, C. A. Drug resistance against HCV NS3\/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc. Natl Acad. Sci. USA 107, 20986\u201320991 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"692_CR208","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31210-w","volume":"13","author":"AM Shaqra","year":"2022","unstructured":"Shaqra, A. M. et al. Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance. Nat. Commun. 13, 3556 (2022). Applying the concept of a substrate envelope to the SARS-CoV-2 Mpro, with analysis of novel Mpro inhibitors.","journal-title":"Nat. Commun."},{"key":"692_CR209","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.77433","volume":"11","author":"JM Flynn","year":"2022","unstructured":"Flynn, J. M. et al. Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms. eLife 11, e77433 (2022).","journal-title":"eLife"},{"key":"692_CR210","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jmb.2012.09.014","volume":"424","author":"Z Deng","year":"2012","unstructured":"Deng, Z. et al. Deep sequencing of systematic combinatorial libraries reveals \u03b2-lactamase sequence constraints at high resolution. J. Mol. Biol. 424, 150\u2013167 (2012).","journal-title":"J. Mol. Biol."},{"key":"692_CR211","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1093\/molbev\/msu081","volume":"31","author":"E Firnberg","year":"2014","unstructured":"Firnberg, E., Labonte, J. W., Gray, J. J. & Ostermeier, M. A comprehensive, high-resolution map of a gene\u2019s fitness landscape. Mol. Biol. Evol. 31, 1581\u20131592 (2014).","journal-title":"Mol. Biol. Evol."},{"key":"692_CR212","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/protein\/gzw015","volume":"29","author":"BT Porebski","year":"2016","unstructured":"Porebski, B. T. & Buckle, A. M. Consensus protein design. Protein Eng. Des. Sel. 29, 245\u2013251 (2016).","journal-title":"Protein Eng. Des. Sel."},{"key":"692_CR213","doi-asserted-by":"crossref","first-page":"11275","DOI":"10.1073\/pnas.1816707116","volume":"116","author":"M Sternke","year":"2019","unstructured":"Sternke, M., Tripp, K. W. & Barrick, D. Consensus sequence design as a general strategy to create hyperstable, biologically active proteins. Proc. Natl Acad. Sci. USA 116, 11275\u201311284 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"692_CR214","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-11429-w","volume":"10","author":"M de Wispelaere","year":"2019","unstructured":"de Wispelaere, M. et al. Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations. Nat. Commun. 10, 3468 (2019).","journal-title":"Nat. Commun."},{"key":"692_CR215","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1021\/acscentsci.0c00984","volume":"6","author":"HS Haniff","year":"2020","unstructured":"Haniff, H. S. et al. Targeting the SARS-CoV-2 RNA genome with small molecule binders and ribonuclease targeting chimera (RIBOTAC) degraders. ACS Cent. Sci. 6, 1713\u20131721 (2020).","journal-title":"ACS Cent. Sci."},{"key":"692_CR216","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1128\/JVI.77.6.3669-3679.2003","volume":"77","author":"C Trozzi","year":"2003","unstructured":"Trozzi, C. et al. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J. Virol. 77, 3669\u20133679 (2003).","journal-title":"J. Virol."},{"key":"692_CR217","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1128\/AAC.48.6.2260-2266.2004","volume":"48","author":"L Lu","year":"2004","unstructured":"Lu, L. et al. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob. Agents Chemother. 48, 2260\u20132266 (2004).","journal-title":"Antimicrob. Agents Chemother."},{"key":"692_CR218","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.virol.2006.03.045","volume":"351","author":"S Le Pogam","year":"2006","unstructured":"Le Pogam, S. et al. In vitro selected Con1 subgenomic replicons resistant to 2\u2019-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 351, 349\u2013359 (2006).","journal-title":"Virology"},{"key":"692_CR219","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1128\/AAC.47.11.3525-3530.2003","volume":"47","author":"TT Nguyen","year":"2003","unstructured":"Nguyen, T. T. et al. Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor. Antimicrob. Agents Chemother. 47, 3525\u20133530 (2003).","journal-title":"Antimicrob. Agents Chemother."},{"key":"692_CR220","doi-asserted-by":"crossref","first-page":"5230","DOI":"10.1128\/AAC.01209-12","volume":"56","author":"LA Pelosi","year":"2012","unstructured":"Pelosi, L. A., Voss, S., Liu, M., Gao, M. & Lemm, J. A. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob. Agents Chemother. 56, 5230\u20135239 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"692_CR221","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1128\/AAC.01317-07","volume":"52","author":"MF McCown","year":"2008","unstructured":"McCown, M. F. et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob. Agents Chemother. 52, 1604\u20131612 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"692_CR222","doi-asserted-by":"crossref","first-page":"e02558-16","DOI":"10.1128\/AAC.02558-16","volume":"61","author":"TI Ng","year":"2017","unstructured":"Ng, T. I. et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob. Agents Chemother. 61, e02558-16 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"692_CR223","doi-asserted-by":"crossref","first-page":"104574","DOI":"10.1016\/j.antiviral.2019.104574","volume":"170","author":"B Han","year":"2019","unstructured":"Han, B. et al. Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-na\u00efve subjects. Antiviral Res. 170, 104574 (2019).","journal-title":"Antiviral Res."},{"key":"692_CR224","doi-asserted-by":"crossref","first-page":"14416","DOI":"10.1073\/pnas.212532699","volume":"99","author":"J Bukh","year":"2002","unstructured":"Bukh, J. et al. Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proc. Natl Acad. Sci. USA 99, 14416\u201314421 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"692_CR225","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1086\/497142","volume":"192","author":"C Sarrazin","year":"2005","unstructured":"Sarrazin, C. et al. Clinical significance of in vitro replication-enhancing mutations of the hepatitis C virus (HCV) replicon in patients with chronic HCV infection. J. Infect. Dis. 192, 1710\u20131719 (2005).","journal-title":"J. Infect. Dis."},{"key":"692_CR226","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1021\/jm401793m","volume":"57","author":"M Belema","year":"2014","unstructured":"Belema, M. et al. Discovery and development of hepatitis C virus NS5A replication complex inhibitors. J. Med. Chem. 57, 1643\u20131672 (2014).","journal-title":"J. Med. Chem."},{"key":"692_CR227","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41586-021-03990-6","volume":"598","author":"SJF Kaptein","year":"2021","unstructured":"Kaptein, S. J. F. et al. A pan-serotype dengue virus inhibitor targeting the NS3\u2013NS4B interaction. Nature 598, 504\u2013509 (2021).","journal-title":"Nature"},{"key":"692_CR228","first-page":"1","volume":"1","author":"K-C Cheng","year":"2007","unstructured":"Cheng, K.-C., Korfmacher, W. A., White, R. E. & Njoroge, F. G. Lead optimization in discovery drug metabolism and pharmacokinetics\/case study: the hepatitis C virus (HCV) protease inhibitor SCH 503034. Perspect. Med. Chem. 1, 1\u20139 (2007).","journal-title":"Perspect. Med. Chem."},{"key":"692_CR229","doi-asserted-by":"crossref","first-page":"e00221-18","DOI":"10.1128\/mBio.00221-18","volume":"9","author":"ML Agostini","year":"2018","unstructured":"Agostini, M. L. et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9, e00221-18 (2018).","journal-title":"mBio"},{"key":"692_CR230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009929","volume":"17","author":"AM Szemiel","year":"2021","unstructured":"Szemiel, A. M. et al. In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. PLoS Pathog. 17, e1009929 (2021).","journal-title":"PLoS Pathog."},{"key":"692_CR231","doi-asserted-by":"crossref","first-page":"eabo0718","DOI":"10.1126\/scitranslmed.abo0718","volume":"14","author":"LJ Stevens","year":"2022","unstructured":"Stevens, L. J. et al. Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms. Sci. Transl. Med. 14, eabo0718 (2022).","journal-title":"Sci. Transl. Med."},{"key":"692_CR232","first-page":"e02815","volume":"14","author":"D Jochmans","year":"2022","unstructured":"Jochmans, D. et al. The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir. mBio 14, e02815\u2013e02822 (2022). Serial passaging study with Mpro inhibitors in SARS-CoV-2.","journal-title":"mBio"},{"key":"692_CR233","unstructured":"Research involving enhanced potential pandemic pathogen. NIH https:\/\/www.nih.gov\/news-events\/research-involving-potential-pandemic-pathogens (2021)."},{"key":"692_CR234","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nrd2411","volume":"6","author":"MP Manns","year":"2007","unstructured":"Manns, M. P. et al. The way forward in HCV treatment\u2013finding the right path. Nat. Rev. Drug Discov. 6, 991\u20131000 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"692_CR235","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1053\/j.gastro.2018.10.024","volume":"156","author":"TF Baumert","year":"2019","unstructured":"Baumert, T. F., Berg, T., Lim, J. K. & Nelson, D. R. Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges. Gastroenterology 156, 431\u2013445 (2019).","journal-title":"Gastroenterology"},{"key":"692_CR236","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/cpt.2603","volume":"112","author":"RSP Singh","year":"2022","unstructured":"Singh, R. S. P. et al. Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir. Clin. Pharmacol. Ther. 112, 101\u2013111 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"key":"692_CR237","doi-asserted-by":"crossref","first-page":"105521","DOI":"10.1016\/j.antiviral.2022.105521","volume":"211","author":"JR Spengler","year":"2023","unstructured":"Spengler, J. R. et al. Meeting report: 35th international conference on antiviral research in Seattle, Washington, USA \u2013 March 21\u201325, 2022. Antiviral Res. 211, 105521 (2023).","journal-title":"Antiviral Res."},{"key":"692_CR238","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"RECOVERY Collaborative Group.","year":"2021","unstructured":"RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384, 693\u2013704 (2021).","journal-title":"N. Engl. J. Med."},{"key":"692_CR239","unstructured":"EMA initiatives for acceleration of development support and evaluation procedures for COVID-19 treatments and vaccines. EMA https:\/\/www.ema.europa.eu\/en\/documents\/other\/ema-initiatives-acceleration-development-support-evaluation-procedures-covid-19-treatments-vaccines_en.pdf (2022)."},{"key":"692_CR240","unstructured":"COVID-19 Public Health Emergency: general considerations for pre-IND meeting requests for COVID-19 related drugs and biological products. FDA https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/covid-19-public-health-emergency-general-considerations-pre-ind-meeting-requests-covid-19-related (2022)."},{"key":"692_CR241","unstructured":"COVID-19: developing drugs and biological products for treatment or prevention: guidance for industry. FDA https:\/\/www.fda.gov\/media\/137926\/download (2021)."},{"key":"692_CR242","unstructured":"Summary of product characteristics: Maviret. EMA https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/maviret-epar-product-information_en.pdf (2022)."},{"key":"692_CR243","unstructured":"Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment: guidance for industry. FDA https:\/\/www.fda.gov\/files\/drugs\/published\/Human-Immunodeficiency-Virus-1-Infection--Developing-Antiretroviral-Drugs-for-Treatment.pdf (2015)."},{"key":"692_CR244","unstructured":"Chronic hepatitis C virus infection: developing direct-acting antiviral drugs for treatment: guidance for industry. FDA https:\/\/www.fda.gov\/media\/79486\/download (2017)."},{"key":"692_CR245","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1126\/science.abj9488","volume":"373","author":"A Edwards","year":"2021","unstructured":"Edwards, A. & Hartung, I. V. No shortcuts to SARS-CoV-2 antivirals. Science 373, 488\u2013489 (2021).","journal-title":"Science"},{"key":"692_CR246","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1126\/science.abi4708","volume":"373","author":"TA Tummino","year":"2021","unstructured":"Tummino, T. A. et al. Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2. Science 373, 541\u2013547 (2021). Describes the concept of phospholipidosis, and how it confounds drug repositioning screens.","journal-title":"Science"},{"key":"692_CR247","unstructured":"NIAID announces antiviral drug development awards. NIAID https:\/\/www.niaid.nih.gov\/news-events\/niaid-announces-antiviral-drug-development-awards (2022)."},{"key":"692_CR248","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1158\/2159-8290.CD-21-1554","volume":"12","author":"DV Nissley","year":"2022","unstructured":"Nissley, D. V. & McCormick, F. RAS at 40: update from the RAS initiative. Cancer Discov. 12, 895\u2013898 (2022).","journal-title":"Cancer Discov."},{"key":"692_CR249","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/80726","volume":"7","author":"AR Williamson","year":"2000","unstructured":"Williamson, A. R. Creating a structural genomics consortium. Nat. Struct. Biol. 7, 953 (2000).","journal-title":"Nat. Struct. Biol."},{"key":"692_CR250","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2016.18","volume":"3","author":"MD Wilkinson","year":"2016","unstructured":"Wilkinson, M. D. et al. The FAIR Guiding Principles for scientific data management and stewardship. Sci. Data 3, 160018 (2016).","journal-title":"Sci. Data"},{"key":"692_CR251","unstructured":"Highlights of Prescribing Information for VEKLURY. FDA https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/214787Orig1s000lbl.pdf (2020)."},{"key":"692_CR252","unstructured":"Fact sheet for healthcare providers: emergency use authorization for LAGEVRIO (molnupiravir) capsules. FDA https:\/\/www.fda.gov\/media\/155054\/download (2021)."},{"key":"692_CR253","unstructured":"Use of molnupiravir for the treatment of COVID-19. EMA https:\/\/www.ema.europa.eu\/en\/documents\/referral\/lagevrio-also-known-molnupiravir-mk-4482-covid-19-article-53-procedure-assessment-report_en.pdf (2022)."},{"key":"692_CR254","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0006-291X(67)80055-X","volume":"27","author":"I Schechter","year":"1967","unstructured":"Schechter, I. & Berger, A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 27, 157\u2013162 (1967).","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-023-00692-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-023-00692-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-023-00692-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T08:04:19Z","timestamp":1733126659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-023-00692-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":254,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["692"],"URL":"https:\/\/doi.org\/10.1038\/s41573-023-00692-8","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"assertion":[{"value":"4 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors and\/or their employers are involved in COVID drug discovery or development programmes, and may continue to be involved in future programmes. These programmes may lead to the generation of intellectual property for their respective employers, and may directly or indirectly contribute to past, present or future revenue of their respective employers. M.D.H. is an employee of NCATS, A.K. is an employee of Pardes Biosciences, L.A.P. is an employee of Vir Biotechnology, K.S.S. is an employee of Takeda California, Inc., U.S. is an employee of Gilead Sciences, J.A.T. is an employee of Novartis Institutes for Biomedical Research, A.v.D. is an employee of Oxford University, and consults for PostEra, Inc. A.A.L. is an employee of Cambridge University and CSO for PostEra, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}